Project for molecular profiling for lung cancer( genetic mutation testing)

Not Applicable

Conditions: Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung

Registration Number: CTRI/2022/12/048326

Lead Sponsor: Tata Memorial Centre

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1. The availability of sufficient archival tumor tissue specimen

2. Age >= 21 years

3. WHO performance status ï?£ 2

4. Life expectancy of >= 12 weeks

5. Patients should have adequate organ function for potential consideration into clinical trials (routine blood tests are valid within 14 days before enrollment):

o Adequate bone marrow function as shown by: ANC >= 1.0 x 109/L, Platelets >= 75 x 109/L, Hb >= 7.5 g/dL

o Alanine aminotransferase (ALT) and aspirate aminotransferase (AST) normal range (or <=3.0 x ULN if liver metastases are present)

6. Willing to provide signed informed consent

7. Patients whom do not fulfill the above criteria may be discussed on a case-by-case basis with the study team, for potential enrolment

Exclusion Criteria

1. No more than 3 lines of cytotoxic chemotherapy at the time of enrolment

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.To evaluate the molecular epidemiology of NSCLC in Asia via comprehensive, prospective molecular profiling of lung cancer specimens â?? in both resected tumours and small biopsy specimens. <br/ ><br>2.To develop a predictive model based on clinical-pathologic characteristics in Asian NSCLC patients. <br/ ><br>Timepoint: 1.Baseline <br/ ><br>2. 2 years <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
1.To ascertain the extent of access to novel/targeted therapies and immunotherapy for patients found to have an actionable biomarker. <br/ ><br>2.To determine outcomes of patients (PFS and OS) in molecularly defined subgroups of NSCLC. <br/ ><br>Timepoint: 1. 2 years <br/ ><br>2. Till disease Progression and / or till death